Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.75 |
| ▸ | HPGD | P15428 | 12/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.75 |
| ▸ | UBE2N | P61088 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 3/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695260 | 0.85 | ALDH1A1 (0.54) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL1695292 | 0.81 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL1694691 | 0.80 | KDM4E (0.56) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL12499930 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL11235489 | 0.79 | CASP1 (0.55) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL1694952 | 0.78 | KDM4E (0.52) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL18560018 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL14740221 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL25435732 | 0.75 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 | |
| SCHEMBL16200737 | 0.74 | KDM4E (0.48) | ALDH1A1HPGDHSD17B10UBE2NMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2755962-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | ALDH1A1 114/4885HPGD 356/4885HSD17B10 945/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | ALDH1A1 114/4885HPGD 356/4885HSD17B10 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.